The approval of neffy marks the first major advancement in epinephrine delivery for patients over four years of age in more ...

The approval is supported by data from clinical trials, including pharmacodynamic and pharmacokinetic responses in adults and ...

Parents and pediatricians just gained one more tool to combat severe allergic reactions in young kids. San Diego-based ARS ...

“We don’t want fear. There’s no needle, there’s no pain with this product,” he said. “It’s basically like spraying saline ...

neffy 1 mg is the first approved needle-free epinephrine nasal spray for children aged 4 to 30 kg, addressing severe allergic reactions. ARS Pharmaceuticals announced the FDA approval of neffy 1 ...

US FDA approves ARS Pharma’s neffy 1 mg to treat type I allergic reactions for paediatric patients weighing 15 to less than 30 kilograms: San Diego Friday, March 7, 2025, 09:00 ...

The FDA has approved neffy 1 mg epinephrine nasal spray for treating anaphylaxis and other type 1 allergic reactions in ...

Neffy (epinephrine nasal spray) 1mg is approved for the emergency treatment of type 1 allergic reactions in children aged 4 ...

ARS Pharma said it is now working towards refiling ... “If approved, neffy would represent the first-ever needle-free nasal spray epinephrine treatment for people with severe allergic reactions ...

Oppenheimer initiated coverage of ARS Pharmaceuticals (SPRY) with an Outperform rating and $40 price target As the first and only approved needle-free epinephrine product, neffy has the potential ...

and CEO of ARS Pharma. “neffy is a groundbreaking device with a simple, needle-free design that we believe will make schools safer and better prepared to address anaphylaxis. While anaphylaxis ...

Neffy 1 mg is the “first significant innovation” for epinephrine delivery in small children aged 4 years and up in over 35 ...